Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer (vol 26, pg 5544, 2008)

被引：0
|
作者：
Leo, Di
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 11期
关键词：
D O I：
10.1200/JCO.2009.22.9419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1923 / 1923
页数：1
相关论文
共 50 条
  • [41] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
    Cortes, J.
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V.
    Pan, W.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
  • [42] Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)
    Belani, C.
    Ramalingam, S.
    Kalemkerian, G.
    Mok, T.
    Rosell, R.
    Ahn, M. J.
    Sun, L.
    Gates, M.
    Lubiniecki, G. M.
    Govindan, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 507 - 507
  • [43] JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
    Xu, Rui-Hua
    Mai, Hai-Qiang
    Chen, Qiu-Yan
    Chen, Dongping
    Hu, Chaosu
    Yang, Kunyu
    Wen, Jiyu
    Li, Jin-Gao
    Shi, Yingrui
    Jin, Feng
    Xu, Ruilian
    Pan, Jianji
    Qu, Shenhong
    Li, Ping
    Hu, Chunhong
    Liu, Yi-Chun
    Jiang, Yi
    He, Xia
    Wang, Hung-Ming
    Lim, Wan-Teck
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [44] A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
    Brufsky, Adam
    Hoelzer, Karen
    Beck, Thaddeus
    Whorf, Robert
    Keaton, Mark
    Nadella, Padma
    Krill-Jackson, Elisa
    Kroener, Joan
    Middleman, Edward
    Frontiera, Michael
    Paul, Devchand
    Panella, Timothy
    Bromund, Jane
    Zhao, Luping
    Orlando, Mauro
    Tai, Fritz
    Marciniak, Martin D.
    Obasaju, Coleman
    Hainsworth, John
    CLINICAL BREAST CANCER, 2011, 11 (04) : 211 - 220
  • [45] Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study
    Shao, Bin
    Song, Guohong
    Li, Huiping
    Di, Lijun
    Jiang, Hanfang
    Liang, Xu
    Yan, Ying
    Zhang, Ruyan
    Ran, Ran
    Wang, Jing
    Liu, Xiaoran
    You, Miaoning
    JOURNAL OF BUON, 2018, 23 (06): : 1583 - 1590
  • [46] Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial
    Valle, J. W.
    Bousmans, N.
    Zhang, W.
    Walgren, R. A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2016, 27 : vi240
  • [47] Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
    Rugo, Hope S.
    Umanzor, Gerardo A.
    Barrios, Francisco J.
    Vasallo, Rosa H.
    Chivalan, Marco A.
    Bejarano, Suyapa
    Ramirez, Julio R.
    Fein, Luis
    Kowalyszyn, Ruben D.
    Kramer, E. Douglas
    Wang, Hui
    Kwan, Min-Fun R.
    Cutler, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 65 - +
  • [48] Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib plus paclitaxel vs trastuzumab plus paclitaxel as first-line treatment for HER2+metastatic breast cancer (NEfERTT)
    Awada, Ahmad
    Colomer, Ramon
    Bondarenko, Igor
    Inoue, Kenichi
    Badwe, Rajendra A.
    Demetriou, Georgia
    Wang, Xiaojia
    Smirnov, Vitaly
    Lee, Soo-Chin
    Mehta, Ajay O.
    Kim, Sung-Bae
    Shen, Zhen-Zhou
    Bachelot, Thomas Denis
    Goswami, Chanchal
    Deo, S. V. S.
    Bose, Ron
    Wong, Alvin
    Xu, Feng
    Bryce, Richard
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Phase III trial of first-line treatment with gemcitabine plus docetaxel versus gemcitabine plus paclitaxel in women with metastatic breast cancer (MBC): A comparison of different schedules and treatment.
    Del Mastro, Lucia
    Fabi, Alessandra
    Mansutti, Mauro
    De Laurentiis, Michele
    Durando, Antonio
    Colantuoni, Giuseppe
    Zaniboni, Alberto
    Barni, Sandro
    Merlo, Domenico Franco
    Bruzzi, Paolo
    La Torre, Ignazia
    Ceccarelli, Matteo
    Kazeem, Gbenga
    Marchi, Paolo
    Boy, Davide
    Venturini, Marco
    De Placido, Sabino
    Cognetti, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] LOTUS (NCT021 62719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) plus paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).
    Dent, Rebecca Alexandra
    Kim, Sung-Bae
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Isakoff, Steven
    Oliveira, Mafalda
    Saura, Cristina
    Wongchenko, Matthew
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345